Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations Rafael Caparica, MD, - ppt download
![MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/67fdcd54f931874b6e6ffa4ffca44de1124ea7f0/5-Figure1-1.png "MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar")
MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Lung cancer with MET exon 14 skipping mutation | LCTT
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
MET Mutation Associated with Responsiveness to Crizotinib. - Abstract - Europe PMC
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment - Journal of Thoracic Oncology
Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
References in Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Abstract - Europe PMC
Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib - Journal of Thoracic Oncology
An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology | Laboratory Investigation
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Identification of tumor-specific, intronic mutations in Met leading to... | Download Scientific Diagram
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
![PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/df73d74a72129de1592255fc0a74db3d4b45eef3/2-Figure1-1.png "PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar")
PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation | JCO Precision Oncology
